FrancophonIA/ELRC3.0 huggingface dataset:
English: No clinically relevant effects on the pharmacokinetics of either medicinal product are expected when daclatasvir is coadministered with any of the following: PDE-5 inhibitors, medicinal products in the ACE inhibitor class (e.g. enalapril), medicinal products in the angiotensin II receptor antagonist class (e.g. losartan, irbesartan, olmesartan, candesartan, valsartan), disopyramide, propafenone, flecainide, mexilitine, quinidine or antacids.
Danish: Der forventes ingen klinisk relevant indvirkning på farmakokinetikken af hverken det ene eller det andet lægemiddel ved administration af daclatasvir sammen med nogen af følgende: PDE-5-hæmmere, ACE-hæmmere (f.eks. enalapril), angiotensin II-receptorantagonister (f.eks. losartan, irbesartan, olmesartan, candesartan, valsartan), disopyramid, propafenon, flecainid, mexilitin, kinidin eller antacida.
English: The dose of daclatasvir was 60 mg once daily, with dose adjustments for concomitant antiretroviral use (see section 4.5).
Danish: Daclatasvirdosis var 60 mg en gang dagligt med dosisjustering ved samtidig antiretroviral behandling (se pkt.
English: pegIFN/RB V N=6
Danish: pegIFN/RBV N=6
English: Since Daklinza is used in combination with other agents, the contraindications and warnings for those medicinal products are applicable.
Danish: Eftersom Daklinza anvendes i kombination med andre midler, gælder kontraindikationer og advarsler for disse lægemidler.
English: Advanced cirrhosis and post-liver transplant (ALLY-1) In study ALLY-1, the regimen of daclatasvir, sofosbuvir, and ribavirin administered for 12 weeks was evaluated in 113 adults with chronic hepatitis C and Child-Pugh A, B or C cirrhosis (n=60) or HCV recurrence after liver transplantation (n=53).
Danish: Fremskreden cirrose og efter levertransplantation (ALLY-1) I studie ALLY-1 blev behandlingsregimet med daclatasvir, sofosbuvir og ribavirin, administreret i 12 uger, undersøgt hos 113 voksne med kronisk hepatitis C og Child-Pugh A, B eller C cirrose (n=60) eller recidiv af HCV efter levertransplantation (n=53).
English: pegIFN/RB V N=42
Danish: pegIFN/RBV N=42
English: MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS CALENDAR BLISTER (NON-PERFORATED) TEXT
Danish: MINDSTEKRAV TIL MÆRKNING PÅ SMÅ BLISTER ELLER STRIP KALENDERBLISTER (IKKE-PERFORERET) TEKST
English: The dose of Daklinza should be increased to 90 mg once daily when coadministered with efavirenz.
Danish: Dosis af Daklinza bør øges til 90 mg en gang dagligt, når det administreres sammen med efavirenz.
English: Cases of hepatitis B virus (HBV) reactivation, some of them fatal, have been reported during or after treatment with direct-acting antiviral agents.
Danish: Samtidig infektion med HCV/HBV (hepatitis B-virus) Der er rapporteret om tilfælde af reaktivering af hepatitis B-virus (HBV), herunder dødelige tilfælde, under eller efter behandling med direkte virkende antivirale lægemidler.
English: Patients in the daclatasvir treatment group who did not have HCV RNA undetectable at both Weeks 4 and 12 and all placebo-treated patients continued pegIFN/RBV for another 24 weeks.
Danish: Patienterne i daclatasvir behandlingsgruppen, som ikke havde ikkedetekterbart HCV-RNA ved hverken uge 4 og 12 og alle placebo-behandlede patienter fortsatte med pegIFN/RBV i yderligere 24 uger.
English: Daklinza should not be used during pregnancy or in women of childbearing potential not using contraception (see section 4.4).
Danish: Daklinza bør ikke anvendes under graviditeten og til kvinder i den fertile alder, som ikke anvender kontraception (se pkt.
English: Patient demographics and baseline disease characteristics are summarised in Table 10.
Danish: Patienternes demografiske data og vigtigste sygdomskarakteristika ved baseline er vist i tabel 10.
English: Pack size of 28 film-coated tablets in non-perforated calendar blisters.
Danish: Pakningsstørrelse med 28 filmovertrukne tabletter i ikke-perforeret kalenderblister.
English: Table 13: Treatment outcomes, daclatasvir in combination with peginterferon alfa and ribavirin (pegIFN/RBV), treatment-naïve patients with HCV genotype 4
Danish: Tabel 13: Behandlingsresultater, daclatasvir i kombination med peginterferon alfa og ribavirin (pegIFN/RBV), behandlingsnaive patienter med HCV-genotype 4
English: mean median
Danish: gennemsnitlig median
English: Patients without cirrhosis
Danish: Patienter uden cirrose
English: 200 mg every other day
Danish: 200 mg hver anden dag
English: Treatment week 24: ≥25 IU/ml
Danish: Behandlingsuge 24: ≥25 IE/ml
English: Patients achieving virologic response [HCV RNA undetectable at weeks 4 and 12] completed therapy after 24 weeks while those who did not achieve virologic response received an additional 24 weeks of treatment with pegIFN/RBV, to complete a total of 48 weeks of study therapy.
Danish: Patienter, der opnåede virologisk respons [ikke-detekterbart HCV-RNA ved uge 4 og 12], afsluttede behandlingen efter 24 uger, mens patienter, som ikke opnåede virologisk respons, fik yderligere 24 ugers behandling med pegIFN/RBV og gennemførte i alt 48 ugers studiebehandling.
English: > 8.5 to ≤10 g/dL
Danish: >8,5 til ≤10 g/dl
English: Cases of severe bradycardia and heart block have been observed when Daklinza is used in combination with sofosbuvir and concomitant amiodarone with or without other drugs that lower heart rate.
Danish: Der er iagttaget tilfælde af svær bradykardi og hjerteblok ved anvendelse af Daklinza i kombination med sofosbuvir samtidig med amiodaron med eller uden andre hjertefrekvenssænkende lægemidler.
English: Treatmentexperienced*
Danish: Behandlingserfaren*
English: Haemoglobin >12 g/dL
Danish: Hæmoglobin >12 g/dl
English: Buprenorphine/naloxone, 8/2 mg to 24/6 mg once daily individualized dose* (daclatasvir 60 mg once daily)
Danish: Buprenorphin/naloxon, 8/2 mg til 24/6 mg en gang dagligt individuel dosis* (daclatasvir 60 mg en gang dagligt)
English: There are no virologic treatment stopping rules that apply to the combination of Daklinza with sofosbuvir.
Danish: Der er ingen virologiske seponeringsregler, der gælder for kombinationen Daklinza og sofosbuvir.
English: The AUC associated with this dose in males is 19-fold the clinical AUC exposure.
Danish: AUC associeret med denne dosis i hanner er 19 gange større end klinisk AUC-eksponering.
English: The relevance of adding ribavirin to that regimen is unclear (see section 5.1).
Danish: Relevansen af at tilføje ribavirin til behandlingen er ukendt (se pkt.
English: No dose adjustment of Daklinza is required for patients with any degree of renal impairment (see section 5.2).
Danish: Dosisjustering af Daklinza er ikke nødvendig hos patienter med hvilken som helst grad af nyreinsufficiens (se pkt.
English: Table 14: Summary of noted newly emergent HCV NS5A substitutions on treatment or during follow-up in treated non-SVR12 subjects infected with HCV genotypes 1 through 3
Danish: Tabel 14: Oversigt over observerede nyopståede HCV-NS5A-substitutioner under behandling eller followup hos behandlede non-SVR12 forsøgspersoner med HCV-genotype 1-3
English: Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to ribavirin; therefore, extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients (see the Summary of Product Characteristics for ribavirin).
Danish: Den yderste forsigtighed skal derfor udvises for at undgå graviditet hos kvindelige patienter eller hos mandlige patienters kvindelige partnere (se produktresuméet for ribavirin).
English: Daklinza must be administered in combination with other medicinal products for the treatment of chronic HCV infection (see sections 4.1 and 4.2).
Danish: Daklinza skal administreres i kombination med andre lægemidler til behandling af kronisk HCV-infektion (se pkt.
English: Treatment week 12: ≥25 IU/ml
Danish: Behandlingsuge 12: ≥25 IE/ml
English: AI444043 was an open-label, single-arm study of daclatasvir with pegIFN/RBV in treatment-naïve adults with chronic HCV genotype 1 infection who were co-infected with HIV.
Danish: AI444043 var et åbent, enkeltarmsstudie med daclatasvir sammen med pegIFN/RBV hos behandlingsnaive voksne med kronisk HCV-genotype 1-infektion, som samtidigt var inficeret med hiv.
English: No dose adjustment of Daklinza or azithromycin or ciprofloxacin is required.
Danish: Dosisjustering er ikke nødvendig for Daklinza eller azithromycin eller ciprofloxacin.
English: ANTIVIRALS, HIV or HBV Protease inhibitors (PIs) Atazanavir 300 mg/ritonavir 100 mg once daily (daclatasvir 20 mg once daily)
Danish: ANTIVIRALE MIDLER, hiv eller HBV Proteasehæmmere (PI'ere) Atazanavir 300 mg/ritonavir 100 mg en gang dagligt (daclatasvir 20 mg en gang dagligt)
English: Daclatasvir inhibits both viral RNA replication and virion assembly.
Danish: Daclatasvir hæmmer både viral RNA replikation og dannelse af virion.
English: Patients assigned to daclatasvir 60 mg once-daily treatment group who had HCV RNA <LLOQ at Week 4 and undetectable at Week 10 were then randomised to receive another 12 weeks of daclatasvir 60 mg + pegIFN/RBV or placebo + pegIFN/RBV for a total treatment duration of 24 weeks.
Danish: Patienter, som blev placeret i behandlingsgruppen, der fik daclatasvir 60 mg en gang dagligt og som havde HCV-RNA <LLOQ ved uge 4 og ikke-detekterbart HCV-RNA ved uge 10 blev herefter randomiseret til at få yderligere 12 uger med daclatasvir 60 mg + pegIFN/RBV eller placebo + pegIFN/RBV i en samlet i behandlingsperiode på 24 uger.
English: Post-LiverTransplant N=53
Danish: Efter levertransplantation N = 53
English: No data are available on the persistence of daclatasvir resistance-associated substitutions beyond 6 months post-treatment in patients treated with daclatasvir and sofosbuvir with/without ribavirin.
Danish: Der foreligger ingen data for persistensen af daclatasvir-resistensassocierede substitutioner hos patienter, der blev behandlet med daclatasvir og sofosbuvir med/uden ribavirin, udover 6 måneder efter afsluttet behandling.
English: Expected due to inhibition of P-gp by daclatasvir:
Danish: Forventes på grund af daclatasvirs hæmning af P-gp:
English: With cirrhosis**
Danish: Med cirrose**
English: For 11 patients, cirrhosis status was missing or inconclusive (FibroTest score >0.48 to
Danish: Hos 11 patienter var cirrosestatus ikke tilgængelig eller inkonklusiv (FibroTest score >0,48 til <0,75 eller APRI >1 til ≤2).
English: Since Daklinza must always be used with other medicines against hepatitis C infection, please read the package leaflets for these medicines.
Danish: Da Daklinza altid skal anvendes sammen med anden medicin mod hepatitis C-infektion, skal du læse indlægssedlerne for disse lægemidler.
English: ↔ Daclatasvir ↔ Rilpivirine
Danish: ↔ Daclatasvir ↔ Rilpivirin
English: Marketing Authorisation Holder Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park Sanderson Road
Danish: Indehaver af markedsføringstilladelsen Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park Sanderson Road
English: Table 4: Interactions and dose recommendations with other medicinal products Medicinal products by therapeutic areas
Danish: Tabel 4: Interaktioner og dosisanbefalinger ved samtidige lægemidler Lægemidler angivet efter terapeutisk område
English: CARDIOVASCULAR AGENTS Antiarrhythmics
Danish: KARDIOVASKULÆRE MIDLER Antiarytmika
English: Very common (may affect more than 1 in 10 people): decreased appetite difficulty sleeping headache shortness of breath nausea fatigue flu-like illness, fever itching, dry skin, unusual hair loss or thinning, rash diarrhoea cough joint pain, aching or tender muscles, not caused by exercise, unusual weakness irritability reduction in red blood cells (anaemia), reduction in white blood cells
Danish: Meget almindelig (kan forekomme hos flere end 1 ud af 10 personer): nedsat appetit søvnbesvær hovedpine åndenød kvalme træthed influenza-lignende sygdom, feber kløe, tør hud, unormalt hårtab eller udtynding af håret, udslæt diarre hoste ledsmerter, smertende eller ømme muskler, som ikke skyldes motion, usædvanlig svaghedsfølelse irritabilitet nedsat mængde røde blodlegemer (anæmi), nedsat mængde hvide blodlegemer
English: Table 4: Interactions and dose recommendations with other medicinal products
Danish: Tabel 4: Interaktioner og dosisanbefalinger ved samtidige lægemidler
English: Daklinza + sofosbuvir (without ribavirin) for 24 weeks
Danish: Daklinza + sofosbuvir (uden ribavirin) i 24 uger
English: Each film-coated tablet contains 30 mg, 60 mg or 90 mg daclatasvir (as dihydrochloride) The other ingredients are - Tablet core: anhydrous lactose (see section 2), microcrystalline cellulose, croscarmellose sodium, silicon dioxide (E551) and magnesium stearate - Film-coating: hypromellose, titanium dioxide (E171), macrogol 400, indigo carmine aluminum lake (E132), yellow iron oxide (E172)
Danish: Øvrige indholdsstoffer: - Tabletkerne: vandfri lactose (se afsnit 2), mikrokrystallinsk cellulose, croscarmellosenatrium, siliconedioxid (E551) og magnesiumstearat - Filmovertræk: hypromellose, titandioxid (E171), macrogol 400, indigo carmine aluminum lake (E132), gul jernoxid (E172)
English: Patients originally assigned to placebo and those in the daclatasvir group who did not achieve HCV RNA <LLOQ at Week 4 and undetectable at Week 10 continued pegIFN/RBV to complete 48 weeks of treatment.
Danish: Patienter, som oprindeligt blev placeret i behandlingsgruppen, der fik placebo og patienter i daclatasvir-gruppen, som ikke nåede HCV-RNA <LLOQ ved uge 4 og ikke-detekterbart HCV-RNA ved uge 10 fortsattte med pegIFN/RBV og gennemførte 48 ugers behandling.
English: 8 weeks therapy
Danish: 8 ugers behandling
English: It is not known whether Daklinza passes into human breast milk.
Danish: Man ved ikke, om Daklinza udskilles i modermælken.
English: Treatment discontinuation in patients with inadequate on-treatment virologic response during treatment with Daklinza, peginterferon alfa and ribavirin It is unlikely that patients with inadequate on-treatment virologic response will achieve a sustained virologic response (SVR); therefore discontinuation of treatment is recommended in these patients.
Danish: Det er usandsynligt, at patienter med utilstrækkelig virologisk respons under behandlingen vil opnå vedvarende virologisk respons (SVR); derfor anbefales seponering af behandlingen hos disse patienter.
English: No dose adjustment of Daklinza, peginterferon alfa, or ribavirin is required.
Danish: Dosisjustering er ikke nødvendig for Daklinza, peginterferon alfa eller ribavirin.
English: In study ALLY-3, the combination of daclatasvir and sofosbuvir administered for 12 weeks was evaluated in 152 adults infected with HCV genotype 3; 101 patients were treatment-naïve and 51 patients had failed prior antiviral therapy.
Danish: I ALLY-3 studiet blev kombinationen daclatasvir og sofosbuvir administreret i 12 uger til 152 voksne smittet med HCV-genotype 3; 101 patienter var behandlingsnaive, og 51 patienter havde gennemgået mislykket antiviral behandling.
English: Potential for interaction with other medicinal products Daclatasvir is a substrate of CYP3A4, P-gp and organic cation transporter (OCT) 1.
Danish: Daclatasvir er substrat for CYP3A4, P-gp og organisk kationtransporter (OCT) 1.
English: Pack size of 28 film-coated tablets in perforated unit dose blisters.
Danish: Pakningsstørrelser med 28 filmovertrukne tabletter i perforeret enkeltdosisblister.
English: HERBAL SUPPLEMENTS St. John's wort (Hypericum perforatum)
Danish: NATURLÆGEMIDLER Perikon (Hypericum perforatum)
English: End of treatment
Danish: Afsluttet behandling
English: Table 6: Treatment outcomes, daclatasvir in combination with sofosbuvir, HCV genotype 1 in Study AI444040
Danish: Tabel 6: Behandlingsresultater, daclatasvir i kombination med sofosbuvir, HCV-genotype 1 i AI444040-studiet
English: Methadone, 40-120 mg once daily individualized dose* (daclatasvir 60 mg once daily)
Danish: Methadon, 40-120 mg en gang dagligt individuel dosis* (daclatasvir 60 mg en gang dagligt)
English: Patient disposition daclatasvir + sofosbuvir 12 weeks N = 153
Danish: Patientfordeling daclatasvir + sofosbuvir 12 uger N = 153
English: Dose adjustment of Daklinza is recommended when coadministered with strong inhibitors of CYP3A4 (see Table 4).
Danish: Dosisjustering af Daklinza anbefales, når det administreres sammen med potente CYP3A4-hæmmere (se tabel 4).
English: Gastrointestinal disorders very common nausea common diarrhoea, vomiting, abdominal pain, gastrooesophageal reflux disease, constipation, dry mouth, flatulence nausea, diarrhoea, abdominal pain
Danish: Mave-tarm-kanalen meget almindelig kvalme almindelig diarre, opkastning, abdominalsmerter, gastroøsofageal reflukssygdom, obstipation, mundtørhed, flatulens kvalme, diarre, abdominalsmerter
English: Most patients (61%) had IL-28B rs12979860 non-CC genotypes.
Danish: Størstedelen af patienterne (61%) havde IL-28B rs12979860 non-CC-genotyper.
English: Detectable HCV RNA at end of treatment
Danish: Detekterbart HCV-RNA ved slutning af behandling
English: Table 3: Treatment stopping rules in patients receiving Daklinza in combination with peginterferon alfa and ribavirin with inadequate on-treatment virologic response
Danish: Tabel 3: Regler for seponering hos patienter, der får Daklinza i kombination med peginterferon alfa og ribavirin med utilstrækkelig virologisk respons under behandling HCV-RNA
English: Palpitations
Danish: Tabletkerne
English: Administration of Daklinza with verapamil may result in increased concentrations of daclatasvir.
Danish: Administration af Daklinza med verapamil kan medføre øgede koncentrationer af daclatasvir.
English: Contraindications of concomitant use (see section 4.3) Daklinza is contraindicated in combination with medicinal products that strongly induce CYP3A4 and P-gp, e.g. phenytoin, carbamazepine, oxcarbazepine, phenobarbital, rifampicin, rifabutin, rifapentine, systemic dexamethasone, and the herbal product St John's wort (Hypericum perforatum), and thus may lead to lower exposure and loss of efficacy of Daklinza.
Danish: 4.3) Daklinza er kontraindiceret i kombination med lægemidler, som er potente CYP3A4- og P-gp-induktorer, f.eks. phenytoin, carbamazepin, oxcarbazepin, phenobarbital, rifampicin, rifabutin, rifapentin, systemisk dexamethason og naturlægemidlet perikon (Hypericum perforatum), og dermed kan føre til nedsat eksponering og nedsat virkning af Daklinza.
English: In the cirrhosis cohort, 4 patients with hepatocellular carcinoma underwent liver transplantation after 1-71 days of treatment; 3 of the 4 patients received 12 weeks of post-liver transplant treatment extension and 1 patient, treated for 23 days before transplantation, did not receive treatment extension.
Danish: 3 af de 4 patienter fik forlænget behandlingen med 12 uger efter levertransplantationen, og 1 patient, der blev behandlet i 23 dage før transplantation, fik ikke forlænget behandlingen.
English: Discontinue Daklinza, peginterferon alfa and ribavirin
Danish: Seponering af Daklinza, peginterferon alfa og ribavirin
English: In patients who received daclatasvir 60 mg tablet orally followed by 100 µg [13C,15N]-daclatasvir intravenous dose, estimated volume of distribution at steady state was 47 l. In vitro studies indicate that daclatasvir is actively and passively transported into hepatocytes.
Danish: N]-daclatasvir som intravenøs dosis, var det estimerede distributionsvolumen ved steady-state (Vss) 47 l. In vitro-studier viser, at daclatasvir transporteres aktivt og passivt ind i hepatocytter.
English: Administration of Daklinza with any of these calcium channel blockers may result in increased concentrations of daclatasvir.
Danish: Administration af Daklinza med en hvilken som helst af disse calciumantagonister kan medføre øgede koncentrationer af daclatasvir.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Daklinza 30 mg film-coated tablets
Danish: KVALITATIV OG KVANTITATIV SAMMENSÆTNING Daklinza 30 mg filmovertrukne tabletter
English: How to take Daklinza
Danish: Sådan skal du tage Daklinza
English: Daklinza + sofosbuvir for 12 weeks
Danish: Daklinza + sofosbuvir i 12 uger
English: If you become pregnant, stop taking Daklinza and tell your doctor immediately.
Danish: Stop med at tage Daklinza og fortæl det straks til lægen, hvis du bliver gravid, mens du tager Daklinza.
English: ↔ Daclatasvir ↔ Azithromycin or Ciprofloxacin
Danish: ↔ Azithromycin eller ciprofloxacin
English: Expected due to inhibition of OATP 1B1 and/or BCRP by daclatasvir:
Danish: Forventes på grund af daclatasvirs hæmning af OATP 1B1 og/eller BCRP: ↑ Koncentration af statin
English: In addition some medicines may affect the way Daklinza works.
Danish: Omvendt kan anden medicin påvirke virkningen af Daklinza.
English: End of treatment HCV RNA undetectable
Danish: Afsluttet behandling HCV-RNA ikke-detekterbart
English: Lower rates of SVR were observed for patients with cirrhosis (see section 5.1).
Danish: Der blev observeret en lavere forekomst af SVR hos patienter med cirrose (se pkt.
English: Ten percent of patients had compensated cirrhosis, and 75% of patients had IL-28B rs12979860 non-CC genotypes.
Danish: Ti procent af patienterne havde kompenserert cirrose, og 75% af patienterne havde IL-28B rs12979860 non-CC-genotyper.
English: When Daklinza is used in combination with ribavirin, the contraindications and warnings for that medicinal product are applicable.
Danish: Når Daklinza anvendes i kombination med ribavirin gælder kontraindikationerne og advarslerne for ribavirin.
English: ACID REDUCING AGENTS H2-receptor antagonists Famotidine 40 mg single dose (daclatasvir 60 mg single dose)
Danish: SYREHÆMMENDE MIDLER H2-receptorantagonister Famotidin 40 mg enkeltdosis (daclatasvir 60 mg enkeltdosis)
English: Common (may affect up to 1 in 10 people): difficulty sleeping dizziness migraine nausea (feeling sick), diarrhoea, abdominal pain joint pain, aching or tender muscles, not caused by exercise
Danish: Almindelig (kan forekomme hos op til 1 ud af 10 personer): søvnbesvær svimmelhed migræne kvalme, diarre, mavesmerter ledsmerter, smertende eller ømme muskler, som ikke skyldes motion
English: Table 7: Treatment outcomes, daclatasvir in combination with sofosbuvir for 24 weeks, treatment-naïve patients with HCV genotype 2 or 3 in Study AI444040 Genotype 2
Danish: Tabel 7: Behandlingsresultater, daclatasvir i kombination med sofosbuvir i 24 uger, behandlingsnaive patienter med HCV-genotype 2 eller 3 i AI444040-studiet
English: Luxembourg/Luxemburg N.V. Bristol-Myers Squibb Belgium S.A. Tél/Tel: + 32 2 352 76 11
Danish: Bristol-Myers Squibb Belgium S.A. Tél/Tel: + 32 2 352 76 11
English: In study ALLY-2, the combination of daclatasvir and sofosbuvir administered for 12 weeks was evaluated in 153 adults with chronic hepatitis C and HIV co-infection; 101 patients were HCV treatment-naïve and 52 patients had failed prior HCV therapy.
Danish: I studie ALLY-2 blev kombinationen af daclatasvir og sofosbuvir, administreret i 12 uger, undersøgt hos 153 voksne med kronisk hepatitis C og samtidig hiv-infektion; 101 patienter var HCV-behandlingsnaive, og hos 52 patienter havde tidligere HCV-behandling fejlet.
English: If you have any questions, ask your doctor or pharmacist.
Danish: Er du i tvivl, så spørg lægen eller apotekspersonalet.
English: Daklinza + sofosbuvir + ribavirin for 12 weeks Daklinza + sofosbuvir +/- ribavirin for 24 weeks
Danish: Daklinza + sofosbuvir + ribavirin i 12 uger Daklinza + sofosbuvir +/- ribavirin i 24 uger
English: No dose adjustment of Daklinza or maraviroc is required.
Danish: Dosisjustering er ikke nødvendig for Daklinza eller maraviroc.